--- title: "Pre-market hot trades in US stocks: Prudential down 7.42% pre-market; Eli Lilly up 3.89% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/294952072.md" description: "Prudential fell 7.42% in pre-market; Eli Lilly rose 3.89% in pre-market; C3is rose 76.50% in pre-market; Gran Tierra Energy rose 46.85% in pre-market; Julong rose 38.70% in pre-market" datetime: "2026-08-05T10:48:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294952072.md) - [en](https://longbridge.com/en/news/294952072.md) - [zh-HK](https://longbridge.com/zh-HK/news/294952072.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Prudential down 7.42% pre-market; Eli Lilly up 3.89% pre-market **Pre-market Hot Trades in US Stocks** Prudential fell 7.42% in pre-market trading. Based on recent key news: 1. On August 3, Prudential announced the repurchase and cancellation of 273,293 ordinary shares at a repurchase price of £10.87 per share, leading to a decline in stock price. This move reduced the company's issued shares to 2,504,166,257 shares. 2. On August 4, Prudential repurchased another 268,144 ordinary shares at an average repurchase price of £11.25 per share, further reducing the issued shares to 2,503,627,395 shares. 3. On August 4, UBS raised Prudential's target stock price from 1,470 pence to 1,515 pence, but this did not prevent the stock price from falling. Market volatility is significant, and macroeconomic dynamics need to be monitored. Eli Lilly rose 3.89% in pre-market trading. Based on recent key news: 1. On August 3, Eli Lilly's pancreatic cancer therapy Olomorasib received FDA breakthrough therapy designation. This news boosted market confidence in Eli Lilly's innovative drugs, driving the stock price up. 2. On August 4, Eli Lilly signed a clinical trial collaboration agreement with Australia's Amplia Therapeutics. The agreement aims to test Amplia's experimental cancer drug in combination with Eli Lilly's KRAS inhibitor Olomorasib, further enhancing Eli Lilly's market prospects. 3. On August 2, the market is highly focused on the upcoming US earnings season and non-farm payroll report. As one of the S&P 500 companies, Eli Lilly's earnings report is expected to be positive, further driving the stock price up. The US earnings season and non-farm payroll report are receiving significant attention. **Top Gainers in Pre-market US Stocks** C3IS rose 76.50% in pre-market trading. Based on recent key news: 1. On August 4, C3IS INC conducted two reverse stock splits in early 2026 to maintain listing eligibility while actively purchasing tankers, resulting in a 358% surge in net income after adjustments in the first quarter. This series of aggressive actions led to significant stock price fluctuations, reflecting the market's response to its high-risk, high-reward strategy. The market reacted strongly to the high-risk strategy, increasing volatility. Gran Tierra Energy rose 46.85% in pre-market trading. Based on recent key news: 1. On August 5, Gran Tierra announced the sale of its Colombia and Ecuador operations to Maurel & Prom for $1.33 billion. This transaction will leave the company debt-free and allow it to focus on Canadian production and new exploration in Azerbaijan, significantly boosting the stock price. 2. On August 5, the company reported a second-quarter net income of $25 million, with adjusted EBITDA of $85 million, benefiting from rising oil prices and improved margins, enhancing its financial position and further boosting market confidence. 3. On August 5, Gran Tierra plans to use part of the sale proceeds for stock buybacks, which is expected to provide direct returns to shareholders and increase investor optimism The rise in oil prices and asset restructuring are driving stock price fluctuations. Julong rose 38.70% in pre-market trading. There has been no significant news regarding Julong recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news ### Related Stocks - [PUK.US](https://longbridge.com/en/quote/PUK.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [CISS.US](https://longbridge.com/en/quote/CISS.US.md) - [GTE.US](https://longbridge.com/en/quote/GTE.US.md) - [JLHL.US](https://longbridge.com/en/quote/JLHL.US.md) ## Related News & Research - [Laekna Advances Obesity Drug LAE102 With Positive Phase I Data](https://longbridge.com/en/news/296933979.md) - [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md) - [Prudential, HCL Group launch 70:30 health insurance joint venture in India](https://longbridge.com/en/news/296446430.md) - [Sarasin & Partners LLP Sells 11,349 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/295214848.md) - [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**